Background: ROS1 gene-rearrangement in non-small-cell lung cancer (NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. The aim of this study is to explore clinicopathological features and clinical efficacy of crizotinib in c-ros oncogene 1 receptor tyrosine kinase (ROS1) positive nonsmall cell lung cancer (NSCLC) . Method: A retrospective analysis of 2617 cases of NSCLC from January 2013 to December 2016, ROS1 fusion gene were detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescent in situ hybridization (FISH) or next-generation sequencing (NGS) technique and part ROS1 fusion gene positive patients were received oral treatment with crizotinib. Result: ROS1 fusion was found in 67 of 2167 cases (2.56%). 21 cases were male and 46 cases were female. The median age was 68 years old. Among these cases, 59 (88.05%) were adenocarcinoma and 8 were non-adenocarcinoma. According the TNM staging,4 cases were Ⅰ-Ⅲa and 63(94.02%) cases were Ⅲb-Ⅳ. EGFR gene status included 60 cases wild type, 1 case co-mutation and 6 cases unknown. There were statistical difference in sex, TNM staging and EGFR gene status between ROS1 fusion gene positive and negetive patients (P<0.001). 23 patients were received oral treatment with crizotinib and PR, SD, PD patients were 13 (56.52%), 5 (21.74%) and 5 (21.74%) respectively. The ORR was 56.52% and DCR was 78.26%. Of all the cases, median PFS was14.5 months and OS was 27.3 months. The one-year PFS was 50.4%.There were no difference of median PFS in age, sex, smoking history, PS score, pathology type, TNM staging ,TP53 gene status, EGFR gene status and the first line crizotinib treatment whether or not by single and multiple factor analysis. The 3/4 grade treatment-related adverse events were gastrointestinal disturbance, followed by increased transaminase. Background: Lung cancer is the most common cause of cancer mortality worldwide. Majority of lung cancer cases occur in lessdeveloped regions. In cancer medicine; bone scintigraphy, a highly sensitive nuclear medicine technique, is often used as a simple whole-body imaging method for metastatic survey. However most recent clinical guidelines on lung cancer management do not recommend the routine use of bone scans to exclude bone metastases, PET/CT (Positron Emission Tomography/Computed Tomography) imaging being the method of choice. In a country where routine PET/CT imaging is not yet available, we investigated bone scan requests in lung cancer patients at our institution since inception of Nuclear Medicine services. Method: Bone scan requests over an eleven-year period (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) at the Nuclear Medicine Centre of the University College Hospital, Ibadan, Nigeria were reviewed. Indications involving lung cancer patients were noted and images as well as reports were reviewed. Standard procedure of planar bone scintigraphy with a gamma camera was employed in all patients following intravenous injection of 15-25mCi 99m Tc-Methylene Diphosphonate (MDP). Result: Of over 6,000 patients who had bone scintigraphy during the period under review, only 12 scans (in eleven patients) were done for detection of bone metastases in known lung cancer patients. The mean age was 50.3 years (range 33 e 68) with male to female ratio of 1.2: 1. Histologic sub-type of all but one was non-small cell lung cancer (NSCLC). All of these patients had skeletal related events, primarily severe bone pains requiring radiation therapy/analgesia, while two had known metastases prior to imaging. Bone scan revealed multiple foci of bone metastases in the vast majority (75%) of the cases. Two cases were negative and one equivocal. Only one required additional tomographic (SPECT) imaging to arrive at a conclusive report. Conclusion:
With an average of one bone scan per year and <0.2% of total bone scans in an eleven-year period, bone scintigraphy appears to be underutilized in the setting of lung cancer in our environment. In the absence of PET/CT imaging, bone scintigraphy still has an important role to play in patients' management and referring physicians are encouraged to embrace this imaging modality. Keywords: Bone scintigraphy, Lung cancer, UCH Ibadan P1.02-02 'Listen To Your Lungs' e An Awareness Campaign from The Marie Keating Foundation A. Baird, 1 L. Yeates 2 1 Lung Cancer Europe, Dublin/IE, 2 The Marie Keating Foundation, Dublin/IE Background: In Ireland, lung cancer is the biggest cancer related killer in both men and women, accounting for over 2,300 cancer cases and over 1,800 deaths. Incidence and mortality rates are projected to increase further in the coming years, particularly in women. In the absence of a national screening programme, there is a need to improve lung cancer awareness, particularly as 1 in 4 Irish people cannot identify one lung cancer symptom. Recent research undertaken by our Foundation has also established that only 7% of adults believe that lung cancer is the leading cause of cancer related deaths in Irish women, and 98% believe that only smokers get lung cancer. These figures underscore the necessity for a national awareness campaign. Method: During Lung Cancer Awareness Month, our Foundation launched an accessible multifaceted national campaign to reach out to, and educate men and women on symptoms and risk, to aid in the early detection of lung cancer. Our campaign aligned with the National Cancer Strategy and focused on symptom awareness, specifically those of a persistent cough, linked with a change in a long-term cough and breathlessness. Our campaign 
